Association between renin-angiotensin system inhibitors and COVID-19 complications.

Sophie LiabeufJulien MoragnyYoussef BennisBenjamin BatteuxEtienne BrochotJean Luc SchmitJean-Philippe LanoixClaire AndrejakOlivier GanryMichel SlamaJulien MaizelYazine MahjoubKamel MasmoudiValérie Gras-Champel

Published in: European heart journal. Cardiovascular pharmacotherapy (2021)

We highlighted a potential safety signal for RASIs, the long-term use of which was independently associated with a higher risk of severe COVID-19 and a poor outcome. Due to the widespread use of this important drug class, formal proof based on clinical trials is needed to better understand the association between RASIs and complications of COVID-19.

Keyphrases

coronavirus disease
sars cov
clinical trial
risk factors
respiratory syndrome coronavirus
randomized controlled trial
early onset
emergency department
drug induced
risk assessment
phase ii
open label
phase iii